Amgen Share Price (NASDAQ: AMGN)

$289.62

▲

1.15

(0.4%)

Last updated on August 27, 2025 at 1:29 AM IST

$₹

Check the interactive Amgen Stock chart to analyse performance

Amgen stock performance

as on August 27, 2025 at 1:29 AM IST

Today's Low:$287.50
Today's High:$289.81
$289.62
0.73%
Downside
Day's Volatility :0.8%
Upside
0.07%
52 Weeks Low:$253.30
52 Weeks High:$339.17
$289.62
12.54%
Downside
52 Weeks Volatility :25.32%
Upside
14.61%

Amgen Stock Returns

Period	Amgen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	3.68%	4.5%	14.5%
6 Months	-5.79%	-7.9%	12.4%
1 Year	-11.71%	-12.3%	21.0%
3 Years	20.58%	7.0%	76.7%

Amgen Inc. Key Stats

Check Amgen key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$288.47
Open	$287.5
Today's High	$289.81
Today's Low	$287.5
Market Capitalization	$158.1B
Today's Volume	$1.7M
52 Week High	$339.17
52 Week Low	$253.3
Revenue TTM	$34.9B
EBITDA	$16.1B
Earnings Per Share (EPS)	$12.22
PE Ratio	24.04
Dividend Yield	3.16%
Profit Margin	18.96%
Quarterly Earnings Growth YOY	0.92%
Return On Equity TTM	99.14%

Stock Returns calculator for Amgen Stock including INR - Dollar returns

The Amgen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Amgen investment value today

Current value as on today

₹93,115

Returns

₹6,885

(-6.88%)

Returns from Amgen Stock

₹11,412 (-11.41%)

Dollar Returns*

₹4,527 (+4.53%)

Indian investors sentiment towards Amgen Stock

-3.45%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Investment in Amgen Shares from India has dropped by -3.45% over the past 30 days, indicating reduced transactional activity.

24%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Amgen Stock from India on INDmoney has increased by 24% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Amgen Stock

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	7654	-708.68	0.90%
Motilal Oswal S&P 500 Index Fund Direct Growth	4346	-82.70	0.29%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	17000	-638.52	1.35%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	846	0.00	1.32%

Global Institutional Holdings in Amgen Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.98%
BlackRock Inc
8.44%
State Street Corp
5.42%
Capital Research & Mgmt Co - Division 3
3.51%
Capital World Investors
3.13%
Morgan Stanley - Brokerage Accounts
3.02%

Analyst Recommendation on Amgen Stock

Rating

Trend

Buy

56%Buy

35%Hold

8%Sell

Based on 37 Wall street analysts offering stock ratings for Amgen(by analysts ranked 0 to 5 stars)

Amgen Share Price Target

What analysts predicted

Upside of 7.69%

Target:

$311.88

Current:

$289.62

Amgen share price target is $311.88, a slight Upside of 7.69% compared to current price of $289.62 as per analysts' prediction.

Amgen Stock Insights

Price Movement
In the last 7 days, AMGN stock has moved down by -2.3%
Increasing Revenue
Amgen Inc. has shown positive revenue growth over the last two quarters. The revenue increased from $8.14 billion to $9.16 billion, which represents an average increase of 11.1% per quarter.
Decreasing Net Profit
Amgen Inc. has experienced a decline in its net profit over the last two quarters. Specifically, the net profit decreased from $1.73 billion to $1.43 billion. This represents an average decrease of 17.2% per quarter.
AMGN vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 8.4% return, outperforming this stock by 20.1%
Price to Sales
Amgen Inc. has a Price-to-Sales Ratio of 4.4, meaning that investors are willing to pay $4.4 for every $1 of sales the company generates. In comparison, Johnson & Johnson has a slightly higher Price-to-Sales Ratio of 4.7, indicating that investors are willing to pay more for their sales.

Amgen Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$23.4B	↓ 1.62%
Net Income	$7.8B	↓ 6.58%
Net Profit Margin	33.57%	↓ 1.78%

	FY20	Y/Y Change
Revenue	$25.4B	↑ 8.83%
Net Income	$7.3B	↓ 7.37%
Net Profit Margin	28.57%	↓ 5.0%

	FY21	Y/Y Change
Revenue	$26.0B	↑ 2.18%
Net Income	$5.9B	↓ 18.87%
Net Profit Margin	22.68%	↓ 5.89%

	FY22	Y/Y Change
Revenue	$26.3B	↑ 1.32%
Net Income	$6.6B	↑ 11.18%
Net Profit Margin	24.89%	↑ 2.21%

	FY23	Y/Y Change
Revenue	$28.2B	↑ 7.09%
Net Income	$6.7B	↑ 2.52%
Net Profit Margin	23.83%	↓ 1.06%

	FY24	Y/Y Change
Revenue	$33.4B	↑ 18.57%
Net Income	$4.1B	↓ 39.11%
Net Profit Margin	12.24%	↓ 11.59%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$7.4B	↓ 9.14%
Net Income	$-113.0M	↓ 114.73%
Net Profit Margin	-1.52%	↓ 10.88%

	Q2 FY24	Q/Q Change
Revenue	$8.4B	↑ 12.64%
Net Income	$746.0M	↓ 760.18%
Net Profit Margin	8.89%	↑ 10.41%

	Q3 FY24	Q/Q Change
Revenue	$8.5B	↑ 1.37%
Net Income	$2.8B	↑ 279.36%
Net Profit Margin	33.28%	↑ 24.39%

	Q4 FY24	Q/Q Change
Revenue	$9.1B	↑ 6.86%
Net Income	$627.0M	↓ 77.84%
Net Profit Margin	6.9%	↓ 26.38%

	Q1 FY25	Q/Q Change
Revenue	$8.1B	↓ 10.31%
Net Income	$1.7B	↑ 175.92%
Net Profit Margin	21.23%	↑ 14.33%

	Q2 FY25	Q/Q Change
Revenue	$9.2B	↑ 12.49%
Net Income	$1.4B	↓ 17.23%
Net Profit Margin	15.62%	↓ 5.61%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$19.0B	↓ 3.26%

	FY20	Y/Y Change
Profit	$19.3B	↑ 1.36%

	FY21	Y/Y Change
Profit	$19.5B	↑ 1.35%

	FY22	Y/Y Change
Profit	$19.9B	↑ 2.01%

	FY23	Y/Y Change
Profit	$19.7B	↓ 0.89%

	FY24	Y/Y Change
Profit	$20.6B	↑ 4.19%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$4.2B	↓ 16.46%

	Q2 FY24	Q/Q Change
Profit	$5.2B	↑ 21.31%

	Q3 FY24	Q/Q Change
Profit	$5.2B	↑ 0.8%

	Q4 FY24	Q/Q Change
Profit	$6.0B	↑ 15.04%

	Q1 FY25	Q/Q Change
Profit	$5.2B	↓ 13.27%

	Q2 FY25	Q/Q Change
Profit	$6.2B	↑ 18.82%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$9.2B	↓ 19.0%
Investing Cash Flow	$5.7B	↓ 60.19%
Financing Cash Flow	$-15.8B	↓ 29.89%

	FY20	Y/Y Change
Operating Cash Flow	$10.5B	↑ 14.72%
Investing Cash Flow	$-5.4B	↓ 194.61%
Financing Cash Flow	$-4.9B	↓ 69.13%

	FY21	Y/Y Change
Operating Cash Flow	$9.3B	↓ 11.77%
Investing Cash Flow	$733.0M	↓ 113.57%
Financing Cash Flow	$-8.3B	↑ 69.94%

	FY22	Y/Y Change
Operating Cash Flow	$9.7B	↑ 4.97%
Investing Cash Flow	$-6.0B	↓ 924.56%
Financing Cash Flow	$-4.0B	↓ 51.19%

	FY23	Y/Y Change
Operating Cash Flow	$8.5B	↓ 12.86%
Investing Cash Flow	$-26.2B	↑ 333.55%
Financing Cash Flow	$21.0B	↓ 621.38%

	FY24	Y/Y Change
Operating Cash Flow	$11.5B	↑ 35.64%
Investing Cash Flow	$-1.0B	↓ 96.01%
Financing Cash Flow	$-9.4B	↓ 144.73%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$689.0M	↑ 28.07%
Investing Cash Flow	$-217.0M	↓ 99.2%
Financing Cash Flow	$-1.7B	↓ 162.02%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$2.5B	↑ 256.89%
Investing Cash Flow	$-217.0M	↑ 0.0%
Financing Cash Flow	$-2.6B	↑ 55.09%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.6B	↑ 45.22%
Investing Cash Flow	$-210.0M	↓ 3.23%
Financing Cash Flow	$-3.7B	↑ 37.83%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$4.8B	↑ 33.6%
Investing Cash Flow	$-402.0M	↑ 91.43%
Financing Cash Flow	$-1.4B	↓ 61.46%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.4B	↓ 70.84%
Investing Cash Flow	$-447.0M	↑ 11.19%
Financing Cash Flow	$-4.1B	↑ 191.9%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$2.3B	↑ 63.91%
Investing Cash Flow	$-389.0M	↓ 12.98%
Financing Cash Flow	$-2.7B	↓ 34.92%

Amgen Technicals Summary

Sell

Neutral

Buy

Amgen is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Amgen Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amgen Inc.	-4.2%	-5.79%	-11.71%	20.58%	14.04%
Eli Lilly And Company	-13.94%	-24.0%	-27.14%	124.22%	371.98%
Johnson & Johnson	7.34%	9.4%	9.49%	9.46%	16.13%
Merck & Co. Inc.	1.52%	-4.52%	-26.75%	-2.57%	-0.36%
Novo Nordisk A/s	-18.38%	-37.11%	-58.34%	4.84%	71.11%
Abbvie Inc	10.06%	2.21%	5.91%	52.89%	120.34%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amgen Inc.	24.04	24.04	0.99	21.08	0.99	0.08	0.03	13.8
Eli Lilly And Company	45.45	45.45	1.03	22.86	0.86	0.17	0.01	20.38
Johnson & Johnson	19.1	19.1	1.09	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	13.14	13.14	0.86	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.65	14.65	1.68	24.84	0.79	0.22	0.03	37.82
Abbvie Inc	99.81	99.81	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amgen Inc.	Buy	$158.1B	14.04%	24.04	18.96%
Eli Lilly And Company	Buy	$623.3B	371.98%	45.45	25.91%
Johnson & Johnson	Buy	$429.7B	16.13%	19.1	25.0%
Merck & Co. Inc.	Buy	$213.1B	-0.36%	13.14	25.79%
Novo Nordisk A/s	Buy	$247.0B	71.11%	14.65	35.61%
Abbvie Inc	Buy	$372.0B	120.34%	99.81	6.45%

Amgen Dividend announcements

Amgen Dividends September, 2025
In the quarter ending September,2025. Amgen has declared dividend of $2.38

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Organization	Amgen
Employees	28000
CEO	Mr. Robert A. Bradway
Industry	Health Technology

Key Management of Amgen Inc.

Name	Title
Mr. Robert A. Bradway	Chairman, CEO & President
Mr. Peter H. Griffith	Executive VP & CFO
Dr. David M. Reese M.D.	Executive VP & CTO
Mr. Murdo Gordon	Executive Vice President of Global Commercial Operations
Dr. James E. Bradner M.D.	Executive Vice President of Research & Development
Mr. Esteban Santos	Executive Vice President of Operations
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance
Mr. Scott Skellenger	Senior VP & Chief Information Officer
Mr. Howard Y. Chang M.D., Ph.D.	Senior VP of Global Research & Chief Scientific Officer
Justin G. Claeys	Vice President of Investor Relations

Important FAQs about investing in AMGN Stock from India :

What is Amgen share price today?

Amgen share price today is $289.62 as on August 27, 2025 at 1:29 AM IST at the close of the market. Amgen share today touched a day high of $289.81 and a low of $287.50.

What is the 52 week high and 52 week low for Amgen share?

Amgen share touched a 52 week high of $339.17 and a 52 week low of $253.30. Amgen stock price today i.e. August 27, 2025 at 1:29 AM IST is closed at $289.62, lower by 14.61% versus the 52 week high.

How to invest in Amgen Stock (AMGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Amgen on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amgen Shares that will get you 0.0052 shares as per Amgen share price of $289.62 per share as on August 27, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Amgen Stock (AMGN) from India?

Indian investors can start investing in Amgen (AMGN) shares with as little as ₹87.6525 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.53 in Amgen stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Amgen share’s latest price of $289.62 as on August 27, 2025 at 1:29 AM IST, you will get 0.0345 shares of Amgen. Learn more about fractional shares .

What are the returns that Amgen has given to Indian investors in the last 5 years?

Amgen stock has given 14.04% share price returns and 18.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?